Abstract Number: 1020 • ACR Convergence 2020
Relationship Between Skin-related Quality of Life, Psychosocial Stress, and Race in Cutaneous Lupus Erythematosus
Background/Purpose: Chronic stress may trigger or exacerbate physiologic pathways that worsen individual health and wellbeing. Stress is associated with the development and progression of skin…Abstract Number: 1397 • ACR Convergence 2020
Clinical and Demographic Features of Morphea Patients with Mucocutaneous Involvement: A Cross Sectional Study from the Morphea of Adults and Children Cohort
Background/Purpose: Morphea is an autoimmune skin condition that produces skin and soft tissue sclerosis. While clinical manifestations of morphea have been well-described, mucocutaneous findings such…Abstract Number: 0260 • ACR Convergence 2020
Does Higher Quality of Care in SLE Improve Quality of Life?
Background/Purpose: Disease activity, damage and quality of life (QOL) are core outcomes in Systemic lupus erythematosus (SLE). ER visits and hospital admissions (non-routine health care…Abstract Number: 1072 • ACR Convergence 2020
Sexual Health Impairment in 62 Female Patients with Idiopathic Inflammatory Myopathies
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of rare diseases characterized by chronic muscle inflammation and multiple organ involvement. These serious clinical manifestations…Abstract Number: 1479 • ACR Convergence 2020
Long-Term Effectiveness of Canakinumab in Autoinflammatory Diseases – Interim Analysis of the CAPS Subgroup from the RELIANCE Registry
Background/Purpose: In the treatment of monogenic autoinflammatory diseases (AID), a heterogeneous group of diseases with excessive interleukin (IL)-1β release and severe systemic and organ inflammation,…Abstract Number: 0326 • ACR Convergence 2020
Flares Among Patients with Psoriatic Arthritis (PsA) – Frequency and Impact on Patient Outcomes: Real-world Survey in the US and Europe
Background/Purpose: Flares in PsA, presenting as periods of acute disease activity, are thought to negatively impact patients’ lives. This has not been extensively studied in…Abstract Number: 1081 • ACR Convergence 2020
Patient-reported Outcomes in Early Autoimmune Inflammatory Myopathies
Background/Purpose: Patient-reported outcomes (PROs) are increasingly used in rheumatology. Such outcomes are under-reported in autoimmune inflammatory myopathies (AIM) especially in incident cohorts. The objective of…Abstract Number: 1494 • ACR Convergence 2020
Patient-Reported Adverse Events, Quality of Life and Treatment Adherence in Juvenile Idiopathic Arthritis: Analysis of Two Large International Cohorts
Background/Purpose: Juvenile idiopathic arthritis (JIA) patients may experience significant medication-related adverse effects (AEs), which may adversely affect health-related quality of life (HRQOL), daily activities and…Abstract Number: 0336 • ACR Convergence 2020
Anxiety and Depression in Psoriatic Arthritis (PsA) – Prevalence and Impact on Patient Reported Outcomes: Real-World Survey in the US and Europe
Background/Purpose: Anxiety and depression are comorbidities among PsA patients. The impact of anxiety and depression on outcomes in PsA patients has not been characterized in…Abstract Number: 1102 • ACR Convergence 2020
Neuropathic Pain in Inflammatory Hand Osteoarthritis(OA) Lowers Quality of Life and May Require Another Approach Than Anti-inflammatory Treatment
Background/Purpose: To investigate whether neuropathic pain is present in patients with inflammatory hand OA, to investigate characteristics of those patients and the impact of neuropathic…Abstract Number: 1577 • ACR Convergence 2020
Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Impact on Function and Patient-Reported Quality of Life Measures Varies Depending on Pattern of Arthritis
Background/Purpose: Immune checkpoint inhibitors (ICIs) have emerged as a paradigm shift in the treatment of malignancies, but can have significant side effects, termed immune related…Abstract Number: 0353 • ACR Convergence 2020
Achievement of Sustained Remission and Low Disease Activity with Secukinumab Improves Quality of Life and Physical Function in Patients with Psoriatic Arthritis: Results from a Randomized Phase 3 Study
Background/Purpose: A treat-to-target approach in psoriatic arthritis (PsA) was recommended by EULAR and GRAPPA to achieve remission (REM) or low disease activity (LDA), by regular…Abstract Number: 1131 • ACR Convergence 2020
Patient Perspective of Helpfulness of Lupus Medications: A Qualitative Study of Medication Use Within the Type 1 and 2 SLE Model
Background/Purpose: Medication management in systemic lupus erythematosus (SLE) is particularly complex given the clinical heterogeneity of symptoms and a wide range of medications used. We…Abstract Number: 1728 • ACR Convergence 2020
Patient-Reported Outcomes of Upadacitinib versus Abatacept in Patients with Rheumatoid Arthritis and an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: 12-Week Results of a Phase 3 Study
Background/Purpose: In patients with active rheumatoid arthritis (RA), treatment with upadacitinib (UPA) has resulted in clinically meaningful improvements in patient-reported outcomes (PROs). This post hoc…Abstract Number: 0378 • ACR Convergence 2020
Itch as the Major Mediator of the Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease with signs and symptoms across multiple domains, including cutaneous manifestations, which can impact health-related quality…
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 25
- Next Page »